Results 101 to 110 of about 9,430 (168)

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation <i>in vivo</i>. [PDF]

Front Immunol
Yu Y, Zhan L, Tang Z.
europepmc   +1 more source

Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study. [PDF]

BioDrugs
Wynne C, Lorch U, Krantz E, Katial R, Ashdown T, Luque M, Sattar A, Rai M, Vashishta L, Petrovic K, Ruffieux R, Leutz S, Berti F.   +12 more
europepmc   +1 more source

Non-Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases. [PDF]

Mediators Inflamm
Gadzhanova S, Roughead E.
europepmc   +1 more source

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study. [PDF]

BioDrugs
Luque M, Zhelyazkova K, Vashishta L, Rai M, Sattar A, Petrovic K, Bucknall R, Leutz S, Berti F.   +8 more
europepmc   +1 more source

Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER. [PDF]

Front Immunol
Chen H, Jiang S, Wang J, Zhang A, Zhu L.
europepmc   +1 more source

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. [PDF]

Ther Adv Gastroenterol
Mesonero F, Zabana Y, Fernández-Clotet A, Leo-Carnerero E, Caballol B, Núñez A, García MJ, Bertoletti F, Bastida G, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González-Partida I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, Rubín de Célix C, Tejido C, Brunet-Mas E, Hernandez-Camba A, Ferrer CS, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro-Huguet MA, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M.   +49 more
europepmc   +1 more source

Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report. [PDF]

Cureus
Fujimori D, Hayashi H, Tahara K, Shoda H, Sawada T.   +4 more
europepmc   +1 more source

Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting. [PDF]

Rheumatol Ther
Arendse R, Rahman P, Baer P, Haaland D, Bessette L, Sholter D, Rachich M, Rampakakis E, Marrache AM, Lehman AJ, Asin-Milan O.   +10 more
europepmc   +1 more source

Comparative risk of tuberculosis infection with different TNF-α inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. [PDF]

Front Immunol
Lv X, Liu Y, Li Y, Zhang Q, Chen S, Liu X, Shi G, Li Y.   +7 more
europepmc   +1 more source

OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study. [PDF]

Inflamm Bowel Dis
Puca P, Masi L, Parello S, Poscia A, Tudor AM, Capobianco I, Pane C, Fidaleo M, Del Chierico F, Palucci I, Laterza L, Napolitano D, Putignani L, Papa A, Lopetuso LR, Petito V, Damiani A, Pani G, Scaldaferri F.   +18 more
europepmc   +1 more source